A Study Published in Vaccines Supports Co-administration of SINOVAC's sIPV with MMR and Hepatitis A Vaccines in Children

BEIJING, January 27, 2026 – Co-administration of SINOVAC's Sabin-strain inactivated poliovirus vaccine (sIPV) with either measles-mumps-rubella (MMR) or inactivated hepatitis A (HepA) vaccines is safe and induces a non-inferior immune response in 18-month-old children, according to a Phase IV study recently published in the peer-reviewed journal Vaccines. The findings provide clinical evidence for integrating sIPV into childhood expanded immunization schedules that require simultaneous vaccinations.

Key Clinical Findings:

Non-inferior Immunogenicity : Co-administration of sIPV with HepA or MMR demonstrated non-inferior immunogenicity compared with solo-administration, maintaining a 100% seroprotection rate for poliovirus types 1, 2, and 3 across all cohorts. Seroconversion rates (SCRs) were high and similar, with all pairwise comparisons meeting the pre-specified non-inferiority margin. No statistically significant differences in geometric mean titers (GMTs) were observed, confirming that simultaneous injection does not interfere with the immune response to any evaluated vaccines.

Consistent Immune Responses Across Co-administered Vaccines: Immune responses for the concurrent vaccines remained robust; the SCR for HepA in the co-administration group was comparable to the HepA alone group (96.6% vs. 98.7%), with no statistically significant difference in the geometric mean concentration (GMC) of antibodies, while seropositivity rates for measles, mumps, and rubella reached 100% in all study cohorts.

Good Safety Profile with Favorable Tolerancey : The concomitant vaccination was well-tolerated. Overall adverse reaction rates within 30 days ranged from 7.3% to 17.4% across groups. Reported reactions were predominantly mild-to-moderate and transient, such as fever and irritability, with no vaccine-related serious adverse events (SAEs) observed throughout the study.

As vaccine-derived poliovirus (VDPV) transmission remains a challenge to global eradication, the World Health Organization (WHO) recommends expanding the use of inactivated poliovirus vaccine (IPV) to replace oral vaccines. This study provides critical clinical evidence for SINOVAC’s sIPV co-administration, supporting the implementation of global immunization strategies.

SINOVAC's sIPV (available in both single-dose and five-dose formulations) has previously received WHO prequalification and is administered widely globally. This research outcome further strengthens the evidence-based support for Sinovac's sIPV in real-world vaccination scenarios.

Up to now, multiple studies have confirmed that Sinovac's sIPV, when co-administered with HepA, MMR, live attenuated hepatitis A vaccine (HepA-L), and diphtheria-tetanus-acellular pertussis vaccine (DTaP) at the age of 18–26 months, demonstrates excellent immunogenicity and safety.

Reference:

The full research paper, titled “Immunogenicity and Safety of Sabin Strain Inactivated Poliovirus Vaccine Booster Dose Administered Separately or Concomitantly with Inactivated Hepatitis A Vaccine or Measles–Mumps–Rubella Combined Attenuated Live Vaccine: An Open-Labelled, Randomized, Controlled, Phase 4 Clinical Trial”, is available at: https://doi.org/10.3390/vaccines13111087.